ArticleAmerican journal of cancer research2023

Lenvatinib plus sintilimab with or without transarterial chemoembolization for intermediate or advanced stage hepatocellular carcinoma: a propensity score-matching cohort study.

Mengran Lang et al.PubMed ↗Full text ↗

No numbers read from the abstract.